Literature DB >> 27481448

Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.

Jeanne Palmer1, Jeannine S McCune2, Miguel-Angel Perales3, David Marks4, Joseph Bubalo5, Mohamad Mohty6, John R Wingard7, Angelo Paci8, Moustapha Hassan9, Christopher Bredeson10, Joseph Pidala11, Nina Shah12, Paul Shaughnessy13, Navneet Majhail14, Jeff Schriber15, Bipin N Savani16, Paul A Carpenter17.   

Abstract

The Practice Guidelines Committee of the American Society of Blood or Marrow Transplantation (ASBMT) sought to develop an evidence-based review about personalizing busulfan-based conditioning. The Committee sought to grade the relevant published studies (June 1, 2008 through March 31, 2016) according to criteria set forth by the Steering Committee for Evidence Based Reviews from ASBMT. Unfortunately, the published literature was too heterogeneous and lacked adequately powered and sufficiently controlled studies for this to be feasible. Despite this observation, the continued interest in this topic led the Practice Guidelines Committee to develop a list of most frequently asked questions (FAQs) regarding personalized busulfan dosing. This "Considerations" document is a list of these FAQs and their responses, addressing topics of practical relevance to hematopoietic cell transplantation clinicians.
Copyright © 2016 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Busulfan; Hematopoietic cell transplantation; Pharmacokinetics; Precision medicine; Therapeutic drug monitoring

Mesh:

Substances:

Year:  2016        PMID: 27481448     DOI: 10.1016/j.bbmt.2016.07.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  33 in total

1.  Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.

Authors:  Jeannine S McCune; Christine M Quinones; James Ritchie; Paul A Carpenter; Erik van Maarseveen; Rosa F Yeh; Claudio Anasetti; Jaap J Boelens; Nelson Hamerschlak; Moustapha Hassan; Hyoung Jin Kang; Yoshinobu Kanda; Angelo Paci; Miguel-Angel Perales; Peter J Shaw; Victoria L Seewaldt; Bipin N Savani; Angela Hsieh; Betsy Poon; Mohamad Mohty; Michael A Pulsipher; Marcelo Pasquini; L Lee Dupuis
Journal:  Biol Blood Marrow Transplant       Date:  2019-05-25       Impact factor: 5.742

2.  Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?

Authors:  Parinda A Mehta; Chie Emoto; Tsuyoshi Fukuda; Brian Seyboth; Ashley Teusink-Cross; Stella M Davies; Jamie Wilhelm; Kirsten Fuller; Alexander A Vinks; Farid Boulad
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-18       Impact factor: 5.742

Review 3.  Opportunities for model-based precision dosing in the treatment of sickle cell anemia.

Authors:  Min Dong; Tomoyuki Mizuno; Alexander A Vinks
Journal:  Blood Cells Mol Dis       Date:  2017-08-09       Impact factor: 3.039

4.  Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.

Authors:  Maura Faraci; Carmine Tinelli; Edoardo Lanino; Stefano Giardino; Massimiliano Leoni; Marta Ferretti; Elio Castagnola; Monica Broglia; Annalisa De Silvestri; Daniela Di Martino; Antonella Bartoli
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

5.  Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia.

Authors:  Takayuki Takachi; Yuki Arakawa; Hiroyoshi Nakamura; Tomoyuki Watanabe; Yuki Aoki; Junjiro Ohshima; Yoshihiro Takahashi; Masahiro Hirayama; Takako Miyamura; Kanji Sugita; Katsuyoshi Koh; Keizo Horibe; Eiichi Ishii; Shuki Mizutani; Daisuke Tomizawa
Journal:  Int J Hematol       Date:  2019-06-14       Impact factor: 2.490

6.  Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?

Authors:  Kristina M Brooks; Paul Jarosinski; Thomas Hughes; Elizabeth Kang; Nirali N Shah; John B Le Gall; Dennis D Hickstein; Suk See De Ravin; Jomy M George; Parag Kumar
Journal:  J Clin Pharmacol       Date:  2017-12-14       Impact factor: 3.126

7.  Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.

Authors:  Jeannine S McCune; Tao Wang; Khalid Bo-Subait; Mahmoud Aljurf; Amer Beitinjaneh; Joseph Bubalo; Jean-Yves Cahn; Jan Cerny; Saurabh Chhabra; Aaron Cumpston; L Lee Dupuis; Hillard M Lazarus; David I Marks; Richard T Maziarz; Maxim Norkin; Tim Prestidge; Shin Mineishi; Maxwell M Krem; Marcelo Pasquini; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2019-03-11       Impact factor: 5.742

8.  A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).

Authors:  Ravi Vij; Jennifer Le-Rademacher; Kristina Laumann; Vera Hars; Kouros Owzar; Tsiporah Shore; Sumithira Vasu; Amanda Cashen; Luis Isola; Thomas Shea; Margarida DeMagalhaes-Silverman; David Hurd; Kenneth Meehan; Frank Beardell; Steven Devine
Journal:  Biol Blood Marrow Transplant       Date:  2019-06-15       Impact factor: 5.742

Review 9.  Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.

Authors:  Rachael Lawson; Christine E Staatz; Christopher J Fraser; Stefanie Hennig
Journal:  Clin Pharmacokinet       Date:  2020-10-30       Impact factor: 6.447

10.  Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy.

Authors:  Kathryn L Bradford; Siyu Liu; Maja Krajinovic; Marc Ansari; Elizabeth Garabedian; John Tse; Xiaoyan Wang; Kit L Shaw; H Bobby Gaspar; Fabio Candotti; Donald B Kohn
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-09       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.